Summary by Moomoo AI
MINGKAND PHARMACEUTICALS RELEASED ITS FIRST QUARTER REPORT FOR 2024 ON 29 APRIL 2024, SHOWING A DECREASE IN REVENUE AND NET PROFIT OF 10.95% AND 10.42%, RESPECTIVELY. The unaudited report showed that the company had an operating income of about RMB 798 billion and a net profit attributable to shareholders of listed companies of about RMB 19.4 billion. Net cash flow generated by operating activities decreased 25.44% with basic earnings per share of $0.67. The company's total assets increased slightly to about RMB 749 billion, while the shareholders' equity belonging to the listed company's shareholders also increased slightly to about RMB 556 billion. During the reporting period, Mincond Pharmaceuticals added more than 300 customers, served more than 6,000 active customers, and successfully synthesized and delivered more than 43 million new compounds. The company continues to strengthen its CRDMO and CTDMO business models and provides integrated new drug R&D and production services globally.